Netupitant 300 mg / palonosetron 0.5 mg Oral Capsule
RxNorm 1552343
Concept Hierarchy & Relationship Mapping
RxNorm Concept Unique Identifier (RxCUI) 1552343 represents a standardized clinical drug concept used for cross-system interoperability. This concept aggregates multiple Atom IDs (AUIs), which are specific naming variations and synonyms used across pharmaceutical databases to ensure accurate medication mapping for: netupitant 300 mg / palonosetron 0.5 mg Oral Capsule.
The following semantic concepts and normalized strings are associated with this clinical entity:
This clinical crossover tool is designed for healthcare professionals, pharmacists, and data analysts to safely compare substitute products and manage medication interoperability.
SCDPrescribable
Semantic Clinical Drug (SCD):
Netupitant 300 mg / palonosetron 0.5 mg Oral Capsule
(Atom ID: 6412231)
SYPrescribable
Synonym (SY):
Netupitant 300 mg / palonosetron 0.5 mg (as palonosetron hydrochloride 0.56 mg) Oral Capsule
(Atom ID: 8238437)
PSNPrescribable
Prescribable Name (PSN):
Netupitant 300 mg / palonosetron 0.5 mg Oral Capsule
(Atom ID: 6412239)
PTPrescribable
Designated preferred name (PT):
Netupitant 300 mg and palonosetron (as palonosetron hydrochloride) 500 microgram oral capsule
(Atom ID: 12871873)
FNPrescribable
Full form of descriptor (FN):
Product containing precisely netupitant 300 mg and palonosetron (as palonosetron hydrochloride) 500 microgram/1 each conventional release oral capsule (clinical drug)
(Atom ID: 12872155)
Patient Education
Netupitant and Palonosetron
The combination of netupitant and palonosetron is used to prevent nausea and vomiting caused by cancer chemotherapy. Netupitant is in a class of medications called neurokinin (NK1) antagonists. It works by blocking neurokinin, a natural substance in the brain that causes nausea and vomiting. Palonosetron is in a class of medications called 5-HT3 receptor antagonists. It works by blocking serotonin, a natural substance in the body that causes nausea and vomiting.
[Learn More]
* Please review the disclaimer below.